LGNDNASDAQHealthcare

LIGAND PHARMACEUTICALS INC

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$306.20

+2.41%

Alpha Vantage · 11/6/2026

Industry: BiotechnologyCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze LGND free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+3.8%

3 months

+3.5%

6 months

+38.3%

1 year

+47.1%

Year to date

+62.0%

52-week range

$181.65 – $322.75

Fundamental snapshot

Latest reported period: Sep 30, 2026

Sharadar reported data

Market cap

$6.12B

P/E

119

P/B

6.4

P/S

24.1

Revenue

$253.83M

Net income

$51.46M

Diluted EPS

2.3

Gross margin

95.20%

Net margin

20.30%

Return on equity

5.20%

Total debt

$1.15B

Cash

$60.07M

Free cash flow

$90.43M

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 30, 2026	$78.75M	-$28.49M	96.60%	-36.20%	-$27.93M
Jun 30, 2026	$63.69M	$48.51M	95.00%	76.20%	$23.99M
Mar 31, 2026	$51.72M	-$13.35M	93.70%	-25.80%	$48.46M
Dec 31, 2025	$59.67M	$44.78M	95.00%	75.10%	$45.91M
Sep 30, 2025	$115.46M	$117.27M	96.70%	101.60%	$12.26M
Jun 30, 2025	$47.63M	$4.85M	93.90%	10.20%	$15.59M
Mar 31, 2025	$45.33M	-$42.45M	89.30%	-93.60%	-$25.66M
Dec 31, 2024	$42.81M	-$31.09M	93.40%	-72.60%	$27.76M

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent LGND news

All market news

Stock Titan·Oct 31, 202648 signal

A director proposes selling 1,209 Ligand Pharmaceuticals (LGND) shares around October 30, 2026.

Ligand Pharmaceuticals Inc. director Jason M. Aryeh has proposed selling 1,209 common shares of the company, valued at approximately $385,185.47, with an anticipated sale date of October 30, 2026. These shares are identified as restricted stock, which he acquired from Ligand Pharmaceuticals Inc. on June 5, 2026. The sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services.

Original source